Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Background T cell engagers are bispecific antibodies recognizing, with one moiety, the CD3ε chain of the T cell receptor and, with the other moiety, specific tumor surface antigens. Crosslinking of CD3 upon simultaneous binding to tumor antigens triggers T cell activation, proliferation and cytokine...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Christian Klein, Marina Bacac, Pablo Umana, Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-07-01
Online Access:	https://jitc.bmj.com/content/9/7/e002582.full